found that the proportion of T cell subsets was unbalanced in tumor patients during the acute infection phase of COVID-19, and the percentages of CD4+ T cells and CD8+ T cells in hematologic tumors were 51% and 42% (13). This evidence concerns the gene CD4 and COVID-19.